GlassScriptPhysician profile
Carroll G Aker
NPI 1245222934
$21,861.28
in general payments reported to CMS, 2019-2025
26 companies · $1,382 in 2025
The $1,382 reported for 2025 was more than what 94% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14K · 2020: $1,649 · 2021: $1,727 · 2022: $849 · 2023: $1,518 · 2024: $1,008 · 2025: $1,382.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,907.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,907.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $14,422.42 | 2019-2025 | Total30, Precision7, Tryptyr |
| Optovue, INC. | $3,246.64 | 2019-2021 | |
| Coopervision INC. | $1,150.03 | 2019-2025 | Myday Contact Lens, Misight Contact Lens, Clariti Contact Lens |
| Johnson & Johnson Vision Care, INC. | $786.48 | 2019-2025 | Acuvue |
| Bausch & Lomb Americas INC. | $511.53 | 2022-2025 | Miebo, Xiidra, Infuse |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $451.71 | 2019-2021 | |
| Abbvie INC. | $265.86 | 2022-2024 | Vuity, Lumigan, Alphagan P |
| Shire North American Group INC | $146.57 | 2019 | |
| Amgen INC. | $125.00 | 2024 | Tepezza |
| Glaukos Corporation | $122.15 | 2024 | Ce-Marked Kxla System |
| Sun Pharmaceutical Industries INC. | $93.39 | 2020-2025 | |
| Kala Pharmaceuticals, INC. | $79.87 | 2021-2022 | |
| Oyster Point Pharma, INC. | $70.96 | 2022-2024 | Tyrvaya |
| Notal Vision, INC. | $56.56 | 2025 | Foresee Home |
| Lkc Technologies, INC. | $45.87 | 2024 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $45.27 | 2024-2025 | Oxervate |
| Allergan, INC. | $38.54 | 2021-2022 | |
| Eyevance Pharmaceuticals LLC | $33.81 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $33.23 | 2020-2022 | |
| Abb Con-Cise Optical Group LLC | $31.37 | 2023 | Contact Lens, Spectacle Lenses |
| Tarsus Pharmaceuticals, INC. | $28.49 | 2025 | Xdemvy |
| Maculogix, INC. | $22.58 | 2019 | |
| Horizon Therapeutics Plc | $15.93 | 2023 | Tepezza |
| Sight Sciences, INC. | $14.94 | 2022 | |
| Astellas Pharma US INC | $13.31 | 2024 | Izervay |
| Lombart Brothers, INC. | $8.77 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carroll Aker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.